Does low-dose methylene blue actually boost energy or focus?
Biohackers from Bryan Johnson on down are microdosing a 19th-century dye for mitochondrial energy, but the human evidence is one small study and the real risk is a dangerous drug interaction.
Published by the editorial staff of Health Trend Wire
A 19th-century dye becomes a biohacker staple
Methylene blue was first synthesized in 1876 as a textile dye, and Paul Ehrlich later found it could kill the malaria parasite, one of the earliest synthetic drugs used in medicine. It has real, established medical uses today: treating methemoglobinemia, reversing certain cases of cyanide poisoning, and managing vasoplegic syndrome during surgery. None of that is what has made it a fixture in longevity circles recently. Bryan Johnson and other biohackers now take small oral doses for energy, focus and mitochondrial support, a use with almost no relationship to why the drug exists in hospitals. It shows up in dropper bottles and capsules marketed as a nootropic, priced far higher than the pharmaceutical-grade version hospitals already use.
The one human study behind the trend
The evidence people cite for the biohacking use case is thin, and it mostly traces back to a single study. A 2016 randomized, placebo-controlled trial gave 26 healthy adults a single 280 milligram oral dose of methylene blue and tested memory and attention using fMRI. The result was real: a 7 percent increase in correct memory-retrieval responses compared with placebo, along with changes in brain activity in regions tied to attention and short-term memory. That is a genuine finding from a well-designed trial, not fabricated. What gets left out of most biohacker pitches is what happened next. A follow-up study by the same research group found methylene blue changed brain connectivity on scans but did not actually improve performance on thinking tasks, and a 2023 review of the broader literature described trial results as mixed and not conclusive. A frequently cited animal study, showing benefits in rats with restricted blood flow to the brain, gets passed around online as if it were human evidence. It is not, and no modern trial has tested daily low-dose methylene blue for everyday energy or focus in otherwise healthy people, which is the actual use case being sold.
“There is not solid data on how methylene blue would work off-label for something like cognitive function.”
What the mechanism theory actually claims
The theory behind the trend is not nonsense on its face. At low concentrations, methylene blue can act as an alternative electron carrier in mitochondria, in principle helping cells produce energy more efficiently, a mechanism shown in cell and animal models. Jamie Alan, a pharmacologist at Michigan State University, put the honest state of things directly: there is not solid data on how methylene blue would work off-label for something like cognitive function. Joe Schwarcz, director of McGill University's Office for Science and Society, went further on the lab research often cited to justify the trend, noting Alzheimer's-related findings are only in the laboratory, in a test tube, with no shown human benefit, and concluded flatly that everyone should stay away from methylene blue, because there's no reason to use it except in a medical setting.
The risk that matters more than the hype
The bigger issue isn't that methylene blue probably does less than advertised, it's a specific, well-documented safety risk: methylene blue inhibits an enzyme called MAO-A, and combined with SSRIs, SNRIs, MAOIs or certain other antidepressants, it can trigger serotonin syndrome, a genuinely dangerous reaction involving agitation, high fever, rapid heart rate and, in severe cases, seizures. This is not a fringe warning. A 2025 study of more than 249,000 surgical patients given methylene blue found over 10 percent were already taking a serotonergic drug, and about one in eight U.S. adults currently takes an antidepressant, which makes this an easy interaction to stumble into without realizing it. Other real risks include hemolysis in people with G6PD deficiency, blue-tinted urine and skin, nausea, and unregulated dosing and purity in wellness grade products compared with pharmaceutical-grade methylene blue. None of those risks are hypothetical: they are the same ones hospitals already manage when they give the drug for its approved uses, just without a clinician watching for them.
“Everyone should stay away from methylene blue, because there's no reason to use it except in a medical setting.”
Our take
Methylene blue has a legitimate medical history and a chemically plausible mechanism for energy, but the human evidence for the biohacking use case is one small, single-dose study, not a body of proof, and the researchers who actually study it are openly skeptical the cognitive benefit is real at all. The serotonin syndrome risk with common antidepressants is the part worth taking seriously, in the same way the injectable peptide BPC-157 trades on animal data and internet enthusiasm well ahead of human safety proof. If you take any psychiatric medication, this is one biohacking trend to skip rather than self-experiment with.
This is general information, not medical advice. Talk to a clinician before changing anything, especially if you are pregnant, nursing, or managing a condition.